Could a cholesterol drug boost lung cancer immunotherapy?
NCT ID NCT05144529
First seen May 06, 2026 · Last updated May 19, 2026 · Updated 2 times
Summary
This study looked at adding evolocumab (a cholesterol-lowering drug) to standard immunotherapy (nivolumab and ipilimumab) for people with advanced non-small cell lung cancer. The goal was to see if the combination was safe and could help the immune system fight cancer better. The study was stopped early and included 19 participants who had not received prior treatment for their metastatic cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER METASTATIC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Duke Univ. Medical Center
Durham, North Carolina, 27710, United States
Conditions
Explore the condition pages connected to this study.